Keel Point’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-8,657
Closed -$530K 273
2021
Q4
$530K Buy
+8,657
New +$598K 0.06% 149
2021
Q2
Sell
-6,052
Closed -$537K 277
2021
Q1
$537K Sell
6,052
-3,671
-38% -$364K 0.05% 153
2020
Q4
$907K Buy
9,723
+4,048
+71% +$323K 0.08% 121
2020
Q3
$362K Sell
5,675
-927
-14% -$54.3K 0.03% 164
2020
Q2
$344K Buy
+6,602
New +$283K 0.04% 151

Other funds holding ARKG

Keel Point's ARKG Position: Q1 2022 in Review

Keel Point sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2022, closing a stake of 8,657 shares — an estimated $530K sold.

Keel Point first reported a position in ARKG in Q2 2020 and held it in 5 quarters. The position peaked at $907K in Q4 2020. 387 funds tracked by Wall St. Rank hold ARKG as of Q1 2022.

  • Keel Point reported no remaining ARK Genomic Revolution ETF position as of Q1 2022 after selling out during the quarter.
  • Keel Point sold 8,657 ARK Genomic Revolution ETF shares in Q1 2022, an estimated $530K.
  • Keel Point first reported a position in ARK Genomic Revolution ETF in Q2 2020 and held it in 5 quarters.
  • Keel Point's ARK Genomic Revolution ETF position peaked at $907K in Q4 2020.
  • 387 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2022.

Based on Keel Point's 13F filing for Q1 2022, filed 27 Apr 2022.